Company intelligence / Profile preview

Append Medical

Ownership: Private
Development stage: Phase 1

Overview

Append Medical is developing a novel transcatheter system for left atrial appendage elimination that leaves no metal implant behind, aiming to reduce stroke risk in non-valvular atrial fibrillation patients. The technology has completed Series A funding and is progressing toward clinical use. The approach addresses limitations of current LAA occlusion devices by eliminating device-related thromboembolism and peri-device leakage risks.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy (transcatheter suture-based LAA elimination system)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Appligator

Phase 1

Indications: Atrial fibrillation, Stroke prevention

Partnerships

MEDX Xelerator incubator

Beyond the preview

Go deeper on Append Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Append Medical.

Explore the full profile